IMV Inc IMVIQ

RE:New presentation looks good

[bikkel78]

good presentation, Fred told that duration is IMV's strong point...and that its really comes to who has the best vaccin in terms of duration and not who has the first approved vaccin. He thinks that in the next few months the attention will shift to companies that show duration.

Also, IMV is leveraging the RSV data in all the discussions with health authorities. So duration...duration....

And the trial will start before the 21th september.